| Written | 2003-10 | Jean-Loup Huret |
| Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France |
| Identity |
| ICD-Topo | C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS |
| ICD-Morpho | 9920/3 Therapy-related myeloid neoplasms |
| Atlas_Id | 1302 |
| Note | This data is extracted from a very large study from an International Workshop on treatment related leukemias - restricted to balanced chromosome aberrations (i.e.: -5/del(5q)and -7/del(7q) not taken into account per see), published in Genes,Chromosomes and Cancer in 2002. |
 | |
| t(8;16)(p11;p13) CREBBP/KAT6A G- banding - Courtesy Melanie Zenger and Claudia Haferlach. R-banded karyotype and FISH using dual color dual fusion probe KAT6A/CREBBP (8p11/16p13)(Cytotest) - Courtesy Karolien Beel, Peter Meeus, Geneviève Ameye and Lucienne Michaux | |
| Clinics and Pathology |
| Disease | Treatment related myelodysplasia (t-MDS) or acute myeloid leukaemias (t-AML) |
| Note | The study included 9 cases; t-MDS with progression to AML accounted for 1 of 9 cases, and t-AML for the remaining 8 cases; no case of acute lymphoblastic leukaemia |
| Epidemiology | t(8;16)(p11;p13) was found in 2% of t-MDS/t-AML; sex ratio: 5M/4F |
| Clinics | Age at diagnosis of the primary disease 33 yrs (range 6-70); age at diagnosis of the t-MDS/t-AML: 41 yrs (range 7-71). Median interval was 17 mths (range: 13-202). Primary disease was a solid tumor in 9 of 9 cases; treatment was radiotherapy in 1 case, chemotherapy in 2 of 9 cases, or both (6/9). Treatment included topoisomerase II inhibitors in 6 of 8 cases and alkylating agents in 7/8. |
| Prognosis | Median survival was very poor: 5 mths, with 39% of patients surviving at 1 yr, and none at 2 yrs. |
| Cytogenetics |
| Additional anomalies | Complex karyotypes were found in 4 of 9 cases. |
| Result of the chromosomal anomaly |
| Description | 5' MOZ -3' CBP |
| Bibliography |
| Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. |
| Block AW, Carroll AJ, Hagemeijer A, Michaux L, van Lom K, Olney HJ, Baer MR |
| Genes, chromosomes & cancer. 2002 ; 33 (4) : 401-412. |
| PMID 11921274 |
| Citation |
| This paper should be referenced as such : |
| Huret, JL |
| t(8;16)(p11;p13) in treatment related leukemia |
| Atlas Genet Cytogenet Oncol Haematol. 2004;8(1):24-24. |
| Free journal version : [ pdf ] [ DOI ] |
| On line version : http://AtlasGeneticsOncology.org/Anomalies/t0816p11p13TreatRelID1302.html |
| Other genes implicated (Data extracted from papers in the Atlas) [ 1 ] |
| Genes | EP300 |
| Translocations implicated (Data extracted from papers in the Atlas) |
| t(8;16)(p11;p13) KAT6A/CREBBP in treatment related leukemia | |
| External links |
| Mitelman database | t(8;16)(p11;p13) |
| arrayMap (UZH-SIB Zurich) | Topo ( C42) Morph ( 9920/3) - [auto + random 100 samples .. if exist ] [tabulated segments] |
| Mitelman database | KAT6A/CREBBP [MCList] KAT6A (8p11.21) CREBBP (16p13.3) |
| TICdb | KAT6A/CREBBP KAT6A (8p11.21) CREBBP (16p13.3) |
| REVIEW articles | automatic search in PubMed |
| Last year articles | automatic search in PubMed |
| All articles | automatic search in PubMed |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Mon Dec 14 18:26:10 CET 2020 |
For comments and suggestions or contributions, please contact us